Modeling of PET data in CNS drug discovery and development

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 40, Issue 3, 2013, Pages 267-279

  Varnäs, Katarina ^a   Varrone, Andrea ^a   Farde, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Kinetic modeling; Microdosing; Positron emission tomography; Receptor occupancy

Indexed keywords

AZD 9272; BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS; DONEPEZIL; DOXEPIN; RACLOPRIDE; SERTRALINE; UNCLASSIFIED DRUG; VERAPAMIL;

BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN REGION; COMPARTMENT MODEL; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG MECHANISM; DRUG RESEARCH; HUMAN; ISOTOPE LABELING; MATHEMATICAL COMPUTING; MEDICAL RESEARCH; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RECEPTOR BINDING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; COMPUTER SIMULATION; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY; TISSUE DISTRIBUTION;

EID: 84878763239     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-013-9320-6     Document Type: Review

References (100)

1. Fischman AJ, Alpert NM, Rubin RH (2002) Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action. Clin Pharmacokinet 41(8):581-602
2. Bergström M, Grahnen A, Långström B (2003) Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 59(5-6):357-366
3. Lee CM, Farde L (2006) Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 27(6):310-316
4. 11C-labeled diphenylhydantoin: positron emission tomography in humans. Neurology 33(5):580-585
5. Bauer M, Langer O, Dal-Bianco P et al (2006) A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clin Pharmacol Ther 80(3):216-227
6. 11C]vinpocetine in human subjects. Acta Neurol Scand 106(6):325-332
7. Gunn RN, Summerfield SG, Salinas CA et al (2012) Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs. J Cereb Blood Flow Metab 32(5):874-883
8. 11C-labeled opiates in the brain of rhesus monkeys. J Pharmacol Exp Ther 230(1):250-255
9. 2A receptors with carbon-11-MDL 100,907. J Nucl Med 39(1):208-214
10. Lundberg T, Lindström LH, Hartvig P et al (1989) Striatal and frontal cortex binding of 11-C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers. Psychopharmacology 99(1):8-12
11. 11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography. Nucl Med Biol 24(6):507-511
12. 11C]venlafaxine: serotonin uptake inhibition, biodistribution and binding in living pig brain. Eur Neuropsychopharmacol 7(3):195-200
13. 11C]doxepin. Nucl Med Biol 31(2):165-171
14. 11C]sertraline distribution in human brain. Arch Pharm Res 35(9):1591-1597
15. 11C-methoxy]donepezil. NeuroImage 46(3):616-623
16. Farde L, Ehrin E, Eriksson L et al (1985) Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci USA 82(11):3863-3867
17. 2-dopamine receptor binding examined in vivo by PET. Acta Psychiatr Scand Suppl 358:67-71
18. Christian BT, Livni E, Babich JW et al (1996) Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography. J Pharmacol Exp Ther 279(1):325-331
19. Kågedal M, Cselényi Z, Nyberg S et al (2012) Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers. NeuroImage 61(4):849-856
20. European Medicines Agency (2004) Position Paper on non-clinical safety studies to support clinical trials with a single microdose. Position paper CPMP/SWP/2599
21. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2006) Guidance for industry, investigators, and reviewers, exploratory IND studies
22. Farde L, Heminway S, Lee CM, McCarthy D, Nordgren I, Nyberg S (2007) Using positron emission tomography (PET) micro-dosing to improve CNS drug development. Regul Rapp 4:2-8
23. Reiman EM, Jagust WJ (2012) Brain imaging in the study of Alzheimer's disease. NeuroImage 61(2):505-516
24. Varrone A, Halldin C (2012) New developments of dopaminergic imaging in Parkinson's disease. Q J Nucl Med Mol Imaging 56(1):68-82
25. Booij J, Berendse HW (2011) Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway. J Neurol Sci 310(1-2):40-43
26. Varrone A, Halldin C (2010) Molecular imaging of the dopamine transporter. J Nucl Med 51(9):1331-1334
27. 18F] cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13(1):24-42
28. Carson RE (2003) Tracer kinetic modeling in PET. In: Bailey DL, Townsend DW, Valk PE, Maisey MN (eds) Positron emission tomography: basic science and clinical practice, 1st edn. Springer, London
29. Slifstein M, Laruelle M (2001) Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol 28(5):595-608
30. Gunn RN, Gunn SR, Cunningham VJ (2001) Positron emission tomography compartmental models. J Cereb Blood Flow Metab 21(6):635-652
31. Ichise M, Meyer JH, Yonekura Y (2001) An introduction to PET and SPECT neuroreceptor quantification models. J Nucl Med 42(5):755-763
32. 2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9(5):696-708
33. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15(3):217-227
34. Leenders KL, Perani D, Lammertsma AA et al (1990) Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain 113:27-47
35. Roland PE, Eriksson L, Stone-Elander S, Widen L (1987) Does mental activity change the oxidative metabolism of the brain? J Neurosci 7(8):2373-2389
36. Innis RB, Cunningham VJ, Delforge J et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27(9):1533-1539
37. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 11(5):735-744
38. 1B receptors in human brain. J Cereb Blood Flow Metab 31:113-123
39. 11C]WAY-100635 in humans: comparison of arterial and reference tissue input functions. J Cereb Blood Flow Metab 20(7):1111-1133
40. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10(5):740-747
41. Slifstein M, Laruelle M (2000) Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med 41(12):2083-2088
42. Ichise M, Toyama H, Innis RB, Carson RE (2002) Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 22(10):1271-1281
43. Wong DF, Gjedde A, Wagner HN Jr (1986) Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. J Cereb Blood Flow Metab 6(2):137-146
44. 11C]deprenyl and dynamic positron emission tomography. J Cereb Blood Flow Metab 11(4):545-556
45. 11C]l-deprenyl-D2) binding in the human brain. Nucl Med Biol 27(1):43-49
46. Rusjan PM, Wilson AA, Mizrahi R et al (2013) Mapping human brain fatty acid amide hydrolase activity with PET. J Cereb Blood Flow Metab 33(3):407-414
47. 11C]-l-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther 85(5):506-512
48. Fowler JS, Logan J, Volkow ND, Wang GJ (2005) Translational neuroimaging: positron emission tomography studies of monoamine oxidase. Mol Imaging Biol 7(6):377-387
49. Farde L, Hall H, Ehrin E, Sedvall G (1986) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231(4735):258-261
50. 11C]raclopride studies. J Cereb Blood Flow Metab 16(1):42-52
51. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. NeuroImage 4(3 Pt 1):153-158
52. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16(5):834-840
53. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23(9):1096-1112
54. 11C]WAY 100635. NeuroImage 32(4):1690-1708
55. Ikoma Y, Watabe H, Shidahara M, Naganawa M, Kimura Y (2008) PET kinetic analysis: error consideration of quantitative analysis in dynamic studies. Ann Nucl Med 22(1):1-11
56. Lappin G, Garner RC (2003) Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2(3):233-240
57. Wagner CC, Langer O (2011) Approaches using molecular imaging technology - use of PET in clinical microdose studies. Adv Drug Deliv Rev 63(7):539-546
58. Renkin EM (1959) Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles. Am J Physiol 197:1205-1210
59. Crone C (1963) The permeability of capillaries in various organs as determined by use of the 'Indicator Diffusion' method. Acta Physiol Scand 58:292-305
60. 11C-labelled verapamil. Clin Pharmacokinet 50(2):111-120
61. 11C-verapamil and PET. J Nucl Med 49(8):1328-1335
62. 11C-N-desmethyl-loperamide. J Nucl Med 51(4):559-566
63. 11C-verapamil in the brain: studies of healthy humans. J Nucl Med 50(8):1267-1275
64. Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A (2008) On the rate and extent of drug delivery to the brain. Pharm Res 25(8):1737-1750
65. Liu X, Vilenski O, Kwan J, Apparsundaram S, Weikert R (2009) Unbound brain concentration determines receptor occupancy: a correlation of drug concentration and brain serotonin and dopamine reuptake transporter occupancy for eighteen compounds in rats. Drug Metab Dispos 37(7):1548-1556
66. Laruelle M, Slifstein M, Huang Y (2003) Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 5(6):363-375
67. Summerfield SG, Lucas AJ, Porter RA et al (2008) Toward an improved prediction of human in vivo brain penetration. Xenobiotica 38(12):1518-1535
68. Maurer TS, Debartolo DB, Tess DA, Scott DO (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33(1):175-181
69. Fridén M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M (2007) In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35(9):1711-1719
70. Smith DA, Di L, Kerns EH (2010) The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9(12):929-939
71. Raboisson P, Breitholtz-Emanuelsson A, Dahllöf H et al (2012) Discovery and characterization of AZD9272 and AZD6538 - two novel mGluR5 negative allosteric modulators selected for clinical development. Bioorg Med Chem Lett 22(22):6974-6979
72. 11C-labeled suicide inactivators and PET. Science 235(4787):481-485
73. Fowler JS, Volkow ND, Logan J et al (1993) Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327. Neurology 43(10):1984-1992
74. Lappin G, Kuhnz W, Jochemsen R et al (2006) Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 80(3):203-215
75. Lappin G, Garner RC (2008) The utility of microdosing over the past 5 years. Expert Opin Drug Metab Toxicol 4(12):1499-1506
76. Lappin G, Shishikura Y, Jochemsen R et al (2010) Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 40(2):125-131
77. 11C]raclopride. Arch Gen Psychiatry 47(3):213-219
78. Pike VW (2009) PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci 30(8):431-440
79. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN (2010) Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 30(1):46-50
80. Karlsson P, Farde L, Halldin C, Sedvall G, Ynddal L, Sloth-Nielsen M (1995) Oral administration of NNC 756 - a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology (Berl) 119(1):1-8
81. 11C]AZ10419369. Psychopharmacology (Berl) 213(2-3):533-545
82. Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45(1):71-76
83. Nordström AL, Farde L, Wiesel FA et al (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33(4):227-235
84. Nord M, Farde L (2011) Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 17(2):97-103
85. Fujita M, Woods SW, Verhoeff NP et al (1999) Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. Eur J Pharmacol 368(2-3):161-172
86. Greenwald MK, Johanson CE, Moody DE et al (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28(11):2000-2009
87. 11C]McN 5652. Psychopharmacology (Berl) 164(4):341-348
88. 11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharmacol Exp Ther 312(1):309-315
89. 11C]DASB positron emission tomography study. Am J Psychiatry 161(5):826-835
90. Suhara T, Takano A, Sudo Y et al (2003) High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 60(4):386-391
91. Grimwood S, Hartig PR (2009) Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol Ther 122(3):281-301
92. Saijo T, Maeda J, Okauchi T et al (2009) Utility of small-animal positron emission tomographic imaging of rats for preclinical development of drugs acting on the serotonin transporter. Int J Neuropsychopharmacol 12(8):1021-1032
93. Takano A, Suhara T, Ichimiya T, Yasuno F, Suzuki K (2006) Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. J Clin Psychopharmacol 26(2):188-191
94. Atack JR, Wong DF, Fryer TD et al (2010) Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy) -3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans. J Pharmacol Exp Ther 332(1):17-25
95. A receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 316(1):410-422
96. 1A receptor occupancy in the monkey brain. Neuropsychopharmacology 22(4):422-429
97. Andrée B, Hedman A, Thorberg SO, Nilsson D, Halldin C, Farde L (2003) Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain. Psychopharmacology (Berl) 167(1):37-45
98. Mathis CA, Bacskai BJ, Kajdasz ST et al (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12(3):295-298
99. Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55(3):306-319
100. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9(4):363-372